Drug intelligence / Profile preview

GT0010X

Development stage: Preclinical
Lead developer: ONODERA GT Pharma
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies

Overview

GT0010X is an investigational adeno-associated virus (AAV) vector-based gene therapy being developed by ONODERA GT Pharma for the treatment of spinal cord injury (SCI), specifically targeting the chronic phase. The therapy is designed to promote the regeneration of damaged nerve fibers and facilitate the recovery of motor functions by delivering therapeutic genetic material to the site of injury. Developed based on research from Professor Hideyuki Okano's laboratory at Keio University, GT0010X aims to overcome the regenerative failure typically seen in chronic spinal cord lesions. As of 2024, the program is in the preclinical stage of development.

Beyond the preview

Go deeper on GT0010X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GT0010X.

Explore the full profile